L. Lucy

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.

R. Greil, H. Döhner, M. Minden, 2015, Blood.

Overall Survival in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with >30% Bone Marrow Blasts Treated with Azacitidine By Cytogenetic Risk Status: Results of the AZA-AML-001 Study

H. Döhner, M. Minden, H. Dombret, 2014 .

124 AZACITIDINE VERSUS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS WITH NEWLY DIAGNOSED AML (>30% MARROW BLASTS) WITH MYELODYSPLASIA-RELATED CHANGES: SUBGROUP ANALYSIS OF THE AZA-AML-001 STUDY

H. Döhner, M. Minden, H. Dombret, 2015 .

Azacitidine (AZA) Versus Conventional Care Regimens (CCR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (>30% Bone Marrow Blasts) with Morphologic Dysplastic Changes: A Subgroup Analysis of the AZA-AML-001 Trial

H. Döhner, M. Minden, H. Dombret, 2014 .

Differential Costs and Outcomes Among Pediatric Oral Antibiotic Formulations Identified from a Large Prescription Database

L. Bowman, L. Lucy, D. Faulkner, 2000, Journal of chemotherapy.

Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial

A. Glasmacher, R. Hájek, H. Avet-Loiseau, 2012, Haematologica.

Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma.

W. Jędrzejczak, S. Rajkumar, J. Zeldis, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Achievement of Red Blood Cell (RBC) Transfusion Independence with Azacitidine (AZA) Leads to Improved Survival In Patients with Higher-Risk Myelodysplasias Regardless of Baseline Transfusion Needs

P. Fenaux, C. Finelli, A. Giagounidis, 2010 .